Quick Answer
Tvardi Therapeutics, Inc. reported Net Income Loss of -$18.21 million for the year ending 2025.
- Tvardi Therapeutics, Inc. showed an increase of +38.0% in Net Income Loss from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$22.20 million | Q2 2017: -$9.30 million | Q3 2017: -$12.44 million | Q4 2017: -$14.18 million | Q1 2018: -$16.77 million | Q2 2018: -$17.19 million | Q3 2018: -$19.40 million | Q4 2018: -$20.65 million | Q1 2019: -$21.96 million | Q2 2019: -$22.96 million | Q3 2019: -$32.84 million | Q4 2019: -$28.61 million | Q1 2020: -$28.92 million | Q2 2020: -$25.07 million | Q3 2020: -$16.51 million | Q4 2020: $78.91 million | Q1 2021: -$23.30 million | Q2 2021: -$30.75 million | Q3 2021: -$1.01 million | Q1 2022: -$27.75 million | Q2 2022: -$4.21 million | Q3 2022: -$23.18 million | Q1 2023: -$26.67 million | Q2 2023: -$31.48 million | Q3 2023: -$28.03 million | Q1 2024: -$4.20 million | Q2 2024: -$6.98 million | Q3 2024: -$5.51 million | Q1 2025: -$9.58 million | Q2 2025: $4.17 million | Q3 2025: -$5.53 million.
- Over the full 14 years of available data (2012 to 2025), Tvardi Therapeutics, Inc.'s Net Income Loss has declined by 190.4%.
- Historical annual values: Fiscal year 2025: -$18.21 million | Fiscal year 2024: -$29.40 million | Fiscal year 2023: -$118.51 million | Fiscal year 2022: -$85.47 million | Fiscal year 2021: -$88.44 million | Fiscal year 2020: $8.41 million | Fiscal year 2019: -$106.37 million | Fiscal year 2018: -$74.01 million | Fiscal year 2017: -$58.13 million | Fiscal year 2016: -$57.28 million | Fiscal year 2015: -$24.69 million | Fiscal year 2014: -$17.75 million | Fiscal year 2013: -$3.96 million | Fiscal year 2012: -$6.27 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: